A German court decision that adopted an “inordinately restrictive interpretation” of the EU supplementary protection certificate (SPC) manufacturing waiver risks undermining the use of the mechanism by European generics and biosimilars manufacturers, off-patent industry body Medicines for Europe has warned.
The SPC manufacturing waiver was hard won by the generics and biosimilars industry, allowing manufacturing for export outside the EU...





